(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36483 A1

(51) International Patent Classification[7]: C07K 14/65, A61K 38/30, 48/00

(21) International Application Number: PCT/GB00/04354

(22) International Filing Date:
15 November 2000 (15.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9926968.0   15 November 1999 (15.11.1999)   GB

(71) Applicant (for all designated States except US): UNIVERSITY COLLEGE LONDON [GB/GB]; Gower Street, London WC1E 6BT (GB).

(72) Inventors; and
(75) Inventors/Applicants (for US only): GOLDSPINK, Geoffrey [GB/GB]; Royal Free and University College Medical School, Dept. of Anatomy and Developmental Biology,

Rowland Hill Street, London NW3 2PF (GB). JOHNSON, Ian [GB/GB]; Royal Free and University College Medical School, Dept. of Anatomy and Developmental Biology, Rowland Hill Street, London NW3 2PF (GB).

(74) Agents: CRESSWELL, Thomas, Anthony et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).

(81) Designated States (national): JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:
— With international search report.
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF THE INSULIN-LIKE-GROWTH FACTOR I ISOFORM MGF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

(57) Abstract: The invention relates to the treatment of neurological disorders with the Insulin-like Growth Factor I (IGF-I) isoform known as mechano growth factor (MGF).

USE OF THE INSULIN-LIKE-GROWTH FACTOR I ISOFORM MGF FOR THE TREATMENT OF NEUROLOGI-
CAL DISORDERS

FIELD OF THE INVENTION

5   The invention relates to the treatment of neurological disorders with the Insulin-like

Growth Factor I (IGF-I) isoform known as mechano growth factor (MGF).

BACKGROUND OF THE INVENTION

10   Mammalian IGF-I polypeptides have a number of isoforms, which arise as a result of

alternative mRNA splicing. Broadly, there are two types of isoform, liver-type

isoforms and non-liver ones. Liver-type isoforms may be expressed in the liver or

elsewhere but, if expressed elsewhere, are equivalent to those expressed in the liver.

They have a systemic action and are the main isoforms in mammals. Non-liver

15   isoforms are less common and some are believed to have an autocrine/paracrine

action. The latter type has been detected in skeletal and cardiac muscle but only

following a mechanical overload.

The terminology for the IGF-I splice variants is based on the liver isoforms (Chew *et*

20   *al.* 1995) and has not fully evolved to take into account those produced by non-liver

tissues. The latter are controlled to some extent by a different promoter (promoter 1)

to the liver IGF-I isoforms, which respond to hormones and are under the control of

promoter 2 (Layall, 1996).

25   For the purposes of this invention, two isoforms are of particular interest. These are

both expressed in skeletal muscle, though it has only recently been appreciated that

two muscle isoforms exist. The first isoform is muscle liver-type IGF-I or L.IGF-I

(systemic type), which is of interest mainly for comparative purposes. The second is

mechano-growth factor or MGF (autocrine/paracrine type).

30

These are alternative splice variants. Exons 1 and 2 are alternative leader exons

(Tobin *et al*, 1990; Jansen *et al*, 1991) with distinct transcription start sites which are differentially spliced to common exon 3. Exons 3 and 4 code for the mature IGF-I peptide (B, C, A and D domains) as well as the first 16 amino acid of the E domain. Exons 5 and 6 each encodes an alternative part of a distinct extension peptide, the E

5   domain. This is followed by the termination codons of precursor IGF-I, 3' untranslated regions and poly(A) addition signal sites (Rotwein *et al*, 1986). A further difference between the two isoforms is that MGF is not glycosylated and is therefore smaller. It has also been shown to be less stable. It may thus have a shorter half-life.

10

It has been shown that MGF, which is not detectable in skeletal muscle unless it is subjected to exercise or stretch (Yang *et al*, 1996), has exons 4, 5 and 6 whilst the muscle L.IGF-I has exons 4 and 6. Exon 5 in MGF has an insert of 52 bp which changes the 3' reading frame and hence the carboxy end of the peptide. In addition,

15   MGF has been detected in overloaded cardiac muscle (Skarli *et al*, 1998).

Functional epitope mapping of IGF-I using a battery of monoclonal antibodies (Mañes *et al*, 1997) has shown that the carboxy terminus (3' end) of IGF-I is important in determining the affinity of the peptide for a particular receptor and/or

20   binding protein.

MGF mRNA is not detected in dystrophic muscle even when it is subjected to stretch. The inability of muscle in both the autosomal- and dystrophin-deficient dystrophies to respond to overload by stretch (Goldspink *et al*, 1996) indicates that

25   the cytoskeleton may be involved in the transduction mechanism. It is probable that there is a basic mechanism that detects muscle overload and which results in the expression of both variant forms of IGF.

Thus, MGF is known to be expressed in skeletal and cardiac muscle tissue in

30   response to stretch and exercise and as a result is believed to be involved in repair of damage to muscle (Yang *et al*, 1996; WO97/33997). This has been confirmed more

recently by McKoy *et al* (1999).

SUMMARY OF THE INVENTION

5   The Inventors have now identified a new and surprising property of MGF.

Plasmids containing MGF DNA operably linked to expression signals capable of
securing expression in muscles were prepared and injected intramuscularly into rats.
Expression of MGF *in vivo* resulted. To investigate the effect of MGF on the

10   animal's nerves, the right-facial nerve was damaged by avulsion in some animals and
crushing in others. Similar experiments were performed with plasmids capable of
expressing L.IGF-I and control experiments were also carried out using equivalent
"empty" plasmids lacking an MGF or L.IGF-I coding sequence, and with non-
operated rats.

15

The surgical procedures carried out normally result in massive motoneurone loss, and
that was the case in the control animals. However, use of L.IGF-I reduced
motoneurone loss to about 50% and use of MGF reduced motoneurone loss to about
20%. Although both isoforms were found to be effective in promoting motoneurone

20   rescue, MGF was, surprisingly, more than twice as effective as L.IGF-I. This opens
up the possibility of using MGF in the treatment of neurological disorders, especially
motoneurone disorders. Additionally, it should be noted that this is the first time that
altered availability of neurotrophic factors to intact adult motoneurones has been
shown to affect a subsequent response to injury and also that this is the first time that

25   intramuscular gene transfer using plasmid DNA has been shown to be an effective
strategy for motoneuroneal rescue.

IGF-I isoforms have specific binding proteins which determine their action,
particularly in terms of which tissues the isoform takes effect in. It appears that the

30   binding protein for MGF is located in the central nervous system (CNS) as well as in
skeletal and cardiac muscle. This may explain its greater effectiveness. Also, the

-4-

fact that MGF is not glycosylated and thus smaller than L.IGF-I may facilitate its transfer from the muscle to the motor neuron cell bodies in the CNS.

These findings have general applicability to the treatment of neurological disorders and are surprising because MGF had previously only been detected in cardiac muscle and skeletal muscle under stretch/exercise. Chew (1995) suggests that an IGF-I Ec form is found in the liver. However, this is detectable in very low amounts and may be due to leaky transcription. Therefore, it had previously been believed that MGF was a muscle-specific isoform whereas it has now emerged that it is also implicated in repairing damage to the nervous system and can thus form the basis of treatments for disorders of the nervous system.

Accordingly, the invention provides:

Use of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion, in the manufacture of a medicament for the treatment of a neurological disorder.

The invention also provides:

Use of a polynucleotide encoding an MGF IGF-I isoform of the invention in the manufacture of a medicament for the treatment of a neurological disorder.

The invention also provides:

A product comprising an MGF IGF-I isoform of the invention or an MGF-encoding polynucleotide of the invention and another neurologically active agent for simultaneous, separate or sequential use in the treatment of a neurological disorder.

The invention also provides:

A pharmaceutical composition comprising an MGF IGF-I isoform of the invention or an MGF-encoding polynucleotide of the invention, another neurologically active

5   agent and a pharmaceutically acceptable carrier.

The invention also provides:

A method of treating a neurological disorder comprising administering to a subject in

10   need of thereof an effective amount of an IGF-I isoform of the invention or a nucleic acid of the invention, optionally in combination with another neurologically active agent.

BRIEF DESCRIPTION OF THE DRAWINGS

15

FIGURE 1:   Total numbers of motoneurones in the facial motor nucleus

KEY

1:    normal   4:   plasmid only - 1 month avulsion

20   2:   1 month crush   5:   IGF-I plasmid - 1 month avulsion

3:    1 month avulsion   6:   MGF plasmid - 1 month avulsion

right: operated side; left: non-operated side

FIGURE 2:   Avulsion (control experiments)

25

(a) Low magnification view of a transverse section through the brainstem at the level of the facial nucleus, 1 month following facial nerve avulsion. Numbers of motoneurones in the facial nucleus of the operated side (b) are markedly reduced compared to the non-operated nucleus (arrow and inset c). 70μm vibratome section

30   stained with YOYO and viewed using epifluorescence.

FIGURE 3:   Plasmid experiments

(a) Low magnification view of the brainstem at the level of the facial nucleus.
Plasmid DNA without any gene insert was injected into the right snout muscle. 7
days later the right facial nerve was avulsed and the animal allowed to survive for 1
month. Like the effect of avulsion only (Figure 1), numbers of motoneurones in the
facial nucleus of the operated side (c) are markedly reduced compared to the non-
operated nucleus (arrow and inset b). 70μm vibratome section stained with YOYO
and viewed using epiflourescence.

FIGURE 4:   MGF plasmid experiments

(a) Low magnification view of the brainstem at the level of the facial nucleus.
Plasmid DNA containing the rat MGF gene was injected into the right snout muscle.
7 days later the right facial nerve was avulsed and the animal allowed to survive for 1
month. Numbers of motoneurones in the facial nucleus of the operated side (b) are
similar to the non-operated nucleus (arrow and inset c). 70μm vibratome section
stained with YOYO and viewed using epiflourescence.

FIGURE 5:   cDNA and amino acid sequence of human MGF, showing its exon
            structure

FIGURE 6:   cDNA and amino acid sequence of rat MGF, showing its exon
            structure

FIGURE 7:   cDNA and amino acid sequence of rabbit MGF, showing its exon
            structure

FIGURE 8:   cDNA and amino acid sequence of human L.IGF-I, showing its exon
            structure

FIGURE 9:   cDNA and amino acid sequence of rat L-IGF-I, showing its exon
             structure

FIGURE 10:   cDNA and amino acid sequence of rabbit L-IGF-I, showing its exon
             structure

FIGURE 11:   Sequence alignment, illustrating exon structure of human, rat and
             rabbit MGF and L-IGF-I, and highlighting similarities and differences

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns the use of MGF in the treatment of neurological
disorders, preferably motoneurone disorders.

MGF polypeptides and polynucleotides

Polypeptides

MGF stands for mechano-growth factor (cf. McKoy *et al* 1999). As discussed above
and explained in more detail in Chew *et al* (1995), Yang *et al* (1996) and McKoy *et
al* (1999), MGF is an alternatively spliced variant of IGF-I. Liver-type IGF-I
comprises amino acids encoded by exons 4 and 6 whereas MGF comprises amino
acids encoded by exons 4, 5 and 6. MGF also has an altered reading frame at its
carboxy terminus as a result of a 52 bp insert in exon 5, and is smaller because it is
not glycosylated. Chew *et al* (1995) and Yang *et al* (1996) did not use the term
MGF, but rather IGF-I Ec, to define the 4-5-6 splice variant. The muscle isoform
that has the Ec domain is now known as MGF (cf McKoy *et al* (1999)). It is now
clear that the particular form of the IGF-I Ec is produced by cardiac and skeletal
muscle but only when they are subjected to mechanical activity.

Herein, MGF is understood to mean any IGF-I polypeptide having the 4-5-6 exon

-8-

structure and the neurological properties identified by the Inventors, as discussed

further below. The exon structure of MGF in human, rat and rabbit is illustrated in

Figures 5, 6 and 7 (SEQ ID NOs. 1/2, 3/4 and 5/6). For comparison, the exon

structure of human, rat and rabbit L.IGF-I is given in Figures 8, 9 and 10 (SEQ ID

5   NOs. 9/10, 11/12 and 13/14), and a comparison between MGF and L-IGF-I is made

in Figure 11.

Preferably, MGF of the invention will have the reading frame which, in native MGF,

is generated by the 52 bp insert mentioned above. Preferably, MGF of the invention

10   will not be glycosylated. However, it may be glycosylated or partially glycosylated

in some embodiments. By partially glycosylated is meant up to 10, 20, 30, 50, 70,

80, 90, 95 or 99% as much glycosylation as L.IGF-I, e.g. containing some, but not

all, of IGF-I's glycosylation sites. The pattern of glycosylation may be the same as

that of L.IGF-I in terms of the type and placement of sugars or it may be different.

15

Preferably, MGFs of the invention comprise exons 3, 4, 5 and 6 on equivalent

sequences. Optionally, they may include exons 1 and/or 2, or equivalent sequences

as well.

20   MGF of the invention may find its origins in any species that has 4-5-6 spliced IGF-I.

Thus, MGF of the invention may have the sequence of human MGF, which is

generally preferred. MGF having the sequence of an animal MGF may also be used,

e.g. rat, rabbit, mouse, cow, sheep, goat, chicken, dog, cat MGF. Preferably, the

species origin of the MGF used will be matched to the species of the subject to be

25   treated. In particular, it is preferred to use human MGF to treat human patients.

The sequences of exons 3, 4, 5 and 6 human MGF (IGF-I-Ec) (SEQ ID NO. 1/2,

Figure 5), rat MGF (SEQ ID NO. 3/4, Figure 6) and rabbit MGF (IGF-I Eb) (SEQ ID

NO. 5/6, Figure 7) are given below, together with their corresponding cDNA

30   sequences. SEQ ID NOs. 1, 3 and 5 are the cDNAs; SEQ ID NOs. 2, 4 and 6 are the

polypeptides. For comparison, the sequences of exons 3, 4 and 6 human (SEQ ID

NO. 9/10, Figure 8), rat (SEQ ID NO. 11/12, Figure 9) and rabbit (SEQ ID NO. 13/14, Figure 10) liver-type IGF-I (L.IGF-I) are also given (see Figure 11 in particular for comparison). Polypeptides having the sequences of SEQ ID NOs. 2, 4 and 6 may be used in preferred embodiments of the invention.

5

Herein, MGF and functional equivalents thereof have the neurological properties identified by the Inventors. Thus, they have the capacity to effect motoneurone rescue. The exact degree of motoneurone rescue will vary from case to case, depending on which MGF is used and under what circumstances. However, with

10   reference to the Examples, MGFs of the invention may be able to reduce motoneurone loss by up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100% in a treated subject compared to an equivalent situation in a non-treated subject. Reduction of motorneurone loss by 70% or more, or 80% more (i.e. to 30% or less or 20% or less) is preferred. The degree of rescue may be calculated using any suitable technique,

15   e.g. a known technique such as Stereology (see the Examples). As a specific test, the techniques used in the Examples, which rely on measuring motoneurone rescue in response to facial nerve avulsion in rats, may be used. However it will be appreciated that this technique may not be ideal for assessing the properties non-rat MGFs. Similar tests may thus be devised using other animal models. For example,

20   tests relating to avulsion of other nerves may be devised. So far as human treatments are concerned, it will generally be necessary to rely on animal models so human MGF may have lower activity in these models than it has *in vivo* in humans.

MGFs having the sequence of naturally occurring MGFs are preferred. However,

25   variant MGFs having the same basic 4-5-6 exon structure and neurological properties discussed herein may also be used.

Polypeptides of the invention may be encoded by polynucleotides as described below.

30

An MGF polypeptide of the invention may consist essentially of the amino acid

-10-

sequence set out in SEQ ID NO. 2, 4 or 6 or a substantially homologous sequence, or of a fragment of either of these sequences, as long as the neurological properties of the invention are maintained. In general, the naturally occurring amino acid sequences shown in SEQ ID NOs. 2, 4 and 6 are preferred. However, the

5   polypeptides of the invention include homologues of the natural sequences, and fragments of the natural sequences and of their homologues, which have the neurological properties of the invention.

In particular, a polypeptide of the invention may comprise:

10

(a)   the polypeptide sequence of SEQ ID NO. 2 (human MGF), 4 (rat MGF), or 6 (rabbit MGF);

(b)   a polypeptide sequence at least 70, 80, 90, 95, 98 or 99% homologous to, a polypeptide of (a);

15   (c)   a sequence comprising the amino acids encoded wholly or partly by exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3, or 5, or a sequence having 70% or greater homology thereto;

(d)   a sequence encoded by a nucleic acid sequence capable of selectively hybridising to a sequence of (a), (b) or (c); or

20   (e)   an allelic variant or species homologue of a sequence of (a).

Allelic Variants

An allelic variant will be a variant which occurs naturally and which will function in
25   a substantially similar manner to the protein of SEQ ID NO. 2, 4 or 6 as defined above. Similarly, a species homologue of the protein will be the equivalent protein which occurs naturally in another species. Such a homologue may occur in any species, preferably a mammalian species, for example a bovine, equine, ovine, feline or canine species; such as cow, horse, sheep or goat, cat, or dog; or in a rodent

30   species other than rat (SEQ ID NO. 4) or rabbit (SEQ ID NO. 6), or in a primate species other than human (SEQ ID NO. 2). Non-mammalian MGFs, for example

-11-

piscine or avian MGFs, e.g. chicken MGF, are also MGFs of the invention. Within any one species, a homologue may exist as several allelic variants, and these will all be considered homologues of the protein of SEQ ID NO. 2, 4 or 6.

5   Allelic variants and species homologues can be obtained by methods known in the art, e.g. by probing suitable cell source with a probe derived from SEQ ID NO. 1, 3 or 5. Clones obtained can be manipulated by conventional techniques to generate a polypeptide of the invention which can be produced by recombinant or synthetic techniques known *per se*.

10

Homologues

A polypeptide of the invention is preferably at least 70% homologous to the protein of SEQ ID NO. 2, 4 or 6 more preferably at least 80 or 90% and more preferably still
15   at least 95, 97 or 99% homologous thereto over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

20

Degrees of homology can be measured by well-known methods, as discussed herein for polynucleotide sequences.

The sequence of the polypeptides of SEQ ID NOs. 2, 4 and 6 and of the allelic
25   variants and species homologues can be modified to provide further polypeptides of the invention.

Substitutions

30   Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. For example, a total of up to 1, 2, 5, 10 or 20 amino acids may be

-12-

substituted over a length of 50, 100 or 200 amino acids in the polypeptides. For example, up to 20 amino acids substituted over any length of 50 amino acids. The modified polypeptide generally retains the neurological properties of the invention, as defined herein. Conservative substitutions may be made, for example according to

5   the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

10

Fragments

Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides and variants thereof, including fragments of the sequence set out

15   in SEQ ID NOs. 2, 4 and 6. Such fragments typically retain the neurological properties of the invention.

Suitable fragments will generally be at least about 20, e.g. at least 20, 50 or 100 amino acids in size. Polypeptide fragments of the polypeptides of SEQ ID NOs. 2, 4

20   and 6 and allelic and species variants thereof may contain one or more (e.g. 2, 3, 5, 5 to 10 or more) substitutions, deletions or insertions, including conservative substitutions. Each substitution, insertion or deletion may be of any length, e.g. 1, 2, 3, 4, 5, 5 to 10 or 10 to 20 amino acids in length.

25   In particular, fragments of the invention may comprise the amino acids encoded by

-13-

exons 4, 5 and 6 of human, rat or rabbit DNA of SEQ ID NO. 1, 3 or 5. The first amino aid of exon 4, Asn, is partly encoded by exon 3 (1 nucleotide) and partly by exon 4 (2 nucleotides). It is preferred that said first amino acid be present, in a fragment of the invention.

Chimeric sequences

MGF polypeptides encoded by chimeric polypeptide sequences of the invention (see below) may be used.

Isolation, purification and modification

Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 70%, e.g. more than 80, 90, 95, 98 or 99% of the polypeptide in the preparation is a polypeptide of the invention.

Polypeptides of the invention may be provided in a form such that they are outside their natural cellular environment. Thus, they may be substantially isolated or purified, as discussed above, or in a cell which they do not occur in nature, e.g. a cell or other plant species, animals, yeast or bacteria.

Polypeptides of the invention may be modified for example by the addition of Histidine residues or a T7 tag to assist their identification or purification or by the addition of a signal sequence to promote their secretion from a cell.

A polypeptide of the invention may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable

-14-

labels include radioisotopes, e.g. ^{125}I, ^{35}S, enzymes, antibodies, polynucleotides and linkers such as biotin.

Polypeptides of the invention may be chemically modified, e.g. post-translationally modified. For example, they may comprise modified amino acid residues. They may also be glycosylated (see above), though MGF is not naturally glycosylated. Such modified polypeptides will be understood to be polypeptides of the invention.

Another possibility is to increase the stability, and hence half life of MGF *in vivo* by altering its sequence, e.g. to make it more amenable to glycosylation by introducing one or more glycosylation sites. Alternatively, modifications can be made that make MGF's primary amino acid structure more resistant to degradation.

The effects of modifications to MGF's sequence can be tested by any suitable method. For example, the binding properties and/or stability of variant MGFs can be tested by comparing them *in vitro* or *in vivo* to those of unmodified MGF.

Polynucleotides

Polynucleotides of the invention encode polypeptides of the invention.

Preferred polynucleotides of the invention comprise a coding sequence encoding a polypeptide having the neurological properties of the invention, which coding sequence is selected from:

(a)   the coding sequence of any one of SEQ ID NO. 1, 3 or 5;

(b)   a sequence capable of selectively hybridising to a sequence of (a), or to a sequence complementary to a sequence of (a);

(c)   a sequence having 70% or more homology to a sequence of (a);

(d)   a sequence which is a fragment of the sequence of any one of (a) to (c); and

(e)   a sequence which differs from that of any one of (a) to (d) but which, owing to the degeneracy of the genetic code, encodes the same polypeptide.

5   Thus, the invention provides polynucleotides comprising the coding sequence as shown in any one of SEQ ID NO. 1, 3 or 5 and variants thereof with related sequences. Polynucleotides of the invention can be used to prepare vectors of the invention.

10   *SEQ ID NOs. 1, 3 and 5*

Preferred polynucleotides of the invention comprise coding sequences as shown in SEQ ID NOs. 1, 3 and 5.

15   *Hybridisable sequences*

A polynucleotide of the invention may hybridise selectively to coding sequence of SEQ ID NO. 1, 3 or 5 at a level significantly above background. Background hybridisation may occur, for example because of other cDNAs present in a cDNA
20   library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence of SEQ ID NO. 1, 3, 5, 7, 9 or 11 is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID NO. 1, 3 or 5. The intensity of interaction may be measured, for example by radiolabelling the probe, e.g. with ^{32}P.
25   Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C, for example 45 to 50, 50 to 55 or 55 to 60°C, e.g. at 50 or 60°C.

30   However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook *et al* (1989), *Molecular Cloning: A Laboratory Manual*).

-16-

For example, if high stringency is required, suitable conditions include 0.2 x SSX at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C. If lower stringency is required, suitable conditions include 2 x SSC at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C.

Stringency typically occurs in a range from about Tm-5°C (5°C below the melting temperature (Tm) of the two sequences hybridising to each other in a duplex) to about 20°C to 25°C below Tm. Thus, according to the invention, a hybridisable sequence may be one which hybridises to SEQ ID NO. 1, 3 or 5 at a temperature of from Tm to Tm-25°C, e.g. Tm to Tm-5°C, Tm-5 to Tm-10°C, Tm-10 to Tm-20°C or Tm-20 to Tm-25°C.

Homologous sequences

A polynucleotide sequence of the invention, will comprise a coding sequence at least 70% preferably at least 80 or 90% and more preferably at least 95, 98 or 99%, homologous to the coding sequence of SEQ ID NO. 1, 3 or 5.

Such homology will preferably apply over a region of at least 20, preferably at least 50, for instance 100 to 500 or more, contiguous nucleotides.

Methods of measuring nucleic acid and polypeptides homology are well known in the art. These methods can be applied to measurement of homology for both polypeptides and nucleic acids of the invention. For example, the UWGCG Package provides the BESTFIT program which can be used to calculate homology (Devereux *et al* (1984), *Nucleic Acids Research* 12, p.387-395).

Similarly, the PILEUP and BLAST algorithms can be used to line up sequences (for example as described in Altschul, S.F. (1993) *J. Mol. Evol.* 30:290-300; Altschul, S.F. *et al* (1990) *J. Mol. Biol.* 215:403-410).

-17-

Many different settings are possible for such programs. According to the invention, the default settings may be used.

In more detail, the BLAST algorithm is suitable for determining sequence similarity
5   and it is described in Altschul *et al* (1990) *J. Mol. Biol.* 215:403-410). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi/nlm.hih.gov/). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued
10   threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions
15   for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The
20   BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci.* USA 89:10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

25   The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g. Karlin and Altschul (1993) *Proc. Natl. Sci.* USA 90:5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For
30   example, a nucleic acid is considered similar to a fused gene or cDNA if the smallest sum probability in comparison of the test nucleic acid to a fused nucleic acid is less

-18-

than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Fragments

5

Also included within the scope of the invention are sequences which are fragments of the sequences of (a) to (c) above but have the neurological properties of the invention.

10   In particular, fragments may comprise exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5.

The first amino acid of exon 4, Asn, is partly encoded by exon 3 and partly by exon 4. It is preferred that the necessary coding bases from exon 3 are present to encode

15   said first amino acid, Asn.

Degenerate sequences

Also included within the scope of the invention are sequences that differ from those

20   of (a) to (d) but which, because of the degeneracy of the genetic code, encode the same protective polypeptides. For example, the invention provides degenerate variants of the sequence of SEQ ID NOs. 1, 3 and 5 that also encode the polypeptide of SEQ ID NOs. 2, 4 and 6.

25   *Complementary sequences*

In addition, the invention provides polynucleotides having sequences complementary to any of the above-mentioned sequences.

30

Chimeric sequences

Chimeric sequences comprising exons from more than one species may also be used.
For example, one or more of exons 3 to 6 may be derived from human and one or
more from rat and/or rabbit.

Further properties

The nucleic sequences of the invention may be of any length as long as they encode a
polypeptide of the invention. A nucleic acid sequence according to the invention
may be a contiguous fragment of the sequence of SEQ ID NO. 1, 3 or 5 or a sequence
that is related to it in any of the ways described above. Alternatively, nucleic acids
of the invention may comprise DNA sequences that are not contiguous in the
sequence of SEQ ID NO. 1, 3 or 5. These sequences may be fragments of the
sequence of SEQ ID NO. 1, 3 or 5 or nucleic acid sequences that are related to such
fragments in any of the ways described above. Nucleic acid sequences of the
invention will preferably comprise at least 50 bases or base pairs, for example 50 to
100, 100 to 500, 500 to 1000 or 1000 to 2000 bases or base pairs.

Any combination of the above-mentioned degrees of homology and minimum sizes
may be used to defined polynucleotides of the invention, with the more stringent
combinations (e.g. higher homology over longer lengths and/or hybridisation under
more stringent conditions)being preferred. Thus, for example a polynucleotide
which is at least 90% homologous over 100, preferably over 200 nucleotides forms
one aspect of the invention, as does a polynucleotide which is at least 95%
homologous over 100 or 200 nucleotides.

Polynucleotides of the invention may comprise DNA or RNA. They may also be
polynucleotides which include within them synthetic or modified nucleotides. A
number of different types of modification to polynucleotides are known in the art.
Modifications may, for example enhance resistance to nucleases and/or enhance

ability to enter cells. For example, phosphorothioate oligonucleotides may be used.
Other deoxynucleotide analogs include methylphosphonates, phosphoramidates,
phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide
phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methyliribonucleotide
5   methylphosphonates. A further possible modification is the addition of acridine or
polylysine chains at the 3' and/or 5' ends of the molecule.

Alternatively mixed backbone oligonucleotides (MBOs) may be used. MBOs
contain segments of phosphothioate oligodeoxynucleotides and appropriately placed
10   segments of modified oligodeoxy- or oligoribonucleotides. MBOs have segments of
phosphorothioate linkages and other segments of other modified oligonucleotides,
such as methylphosphonate, which is non-ionic, and very resistant to nucleases or
2'-O-alkyloliogoribonucleotides. For the purposes of the present invention, it is to be
understood that the polynucleotides described herein may be modified by any
15   method available in the art. Such modifications may be carried out in order to
enhance the *in vivo* activity or lifespan of polynucleotides of the invention.

Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer,
a primer for an alternative amplification reaction, a probe, e.g. labelled with a
20   revealing label by conventional means using radioactive or non-radioactive labels. or
the polynucleotides may be cloned into vectors. Such primers, probes and other
fragments will preferably be at least 10, preferably at least 15 or 20, for example at
least 25, 30 or 40 nucleotides in length. These will be useful in identifying species
homologues and allelic variants as discussed above.

25

Polynucleotides such as a DNA polynucleotides and primers according to the
invention may be produced recombinantly, synthetically, or by any means available
to those of skill in the art. They may also be cloned by standard techniques. The
polynucleotides are typically provided in isolated and/or purified form.

30

In general, primers will be produced by synthetic means, involving a stepwise

-21-

manufacture of the desired nucleic acid sequence one nucleotide at a time.
Techniques for accomplishing this using automated techniques are readily available
in the art.

5   Genomic clones corresponding to the cDNAs of SEQ ID NOs. 1, 3 and 5 containing,
for example introns and promoter regions are also aspects of the invention and may
also be produced using recombinant means, for example using PCR (polymerase
chain reaction) cloning techniques.

10   The 4-5-6 exon pattern of MGF is characteristic of polynucleotides of the invention.
Any suitable method may be used to ensure that this pattern is reflected in the coding
sequence, and thus in the encoded polypeptide. For example, cDNA sequences
lacking introns and splice signals and including the coding sequences of exons 4, 5
and 6 may be used. Alternatively, genomic DNA may be used if it will be correctly
15   spliced in the situation at hand.

Although in general the techniques mentioned herein are well known in the art,
reference may be made in particular to Sambrook *et al* (1989), *Molecular Cloning: A*
Laboratory Manual.
20

Polynucleotides which are not 100% homologous to the sequences of the present
invention but fall within the scope of the invention, as described above, can be
obtained in a number of ways, for example by probing cDNA or genomic libraries
from other plant species with probes derived from SEQ ID NO. 1, 3 or 5. Degenerate
25   probes can be prepared by means known in the art to take into account the possibility
of degenerate variation between the DNA sequences of SEQ ID NO. 1, 3 or 5 and the
sequences being probed for under conditions of medium to high stringency (for
example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to
about 60°C), or other suitable conditions (e.g. as described above).
30

Allelic variants and species homologues may also be obtained using degenerate PCR

-22-

which will use primers designed to target sequences within the variants and homologues encoding likely conserved amino acid sequences. Likely conserved sequences can be predicted from aligning the amino acid sequences of the invention (SEQ ID NO. 2, 4 or 6) with each other and/or with those of any homologous

5   sequences known in the art. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site-directed mutagenesis of
10   sequences of SEQ ID NO. 1, 3 or 5 or allelic variants thereof. This may be useful where, for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequences may be desired in order to introduce restriction enzyme recognition sites, or to alter the properties or function of the polypeptides encoded by
15   the polynucleotides.

The invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement.

20   Polynucleotides, probes or primers of the invention may carry a revealing label. Suitable labels include radiosotopes such as ^{32}P ro ^{35}S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides, probes or primers of the invention and may be detected using techniques known *per se*.

25   **Delivery of MGF to subjects**

MGF and functionally equivalent polypeptides of the invention can be delivered to subjects in need of treatment for neurological disorders by any suitable method. They can be delivered directly, as polypeptides. However, delivery by means of a
30   vector containing a nucleic acid encoding the polypeptide, which is then expressed *in vivo*, is preferred in some situations. MGF has a short half-life and may be most

effective when provided locally at the neuromuscular junction. *In vivo* expression of MGF facilitates localisation and avoids the need for repeated injection.

Nevertheless, there are clinical situations in which peptide delivery will be preferred.
For example, in the case of a stroke or alcohol-related brain damage when neuronal cell death must be prevented as soon as possible, peptide delivery would be preferred. One possibility is to deliver the polypeptide directly in the first instance, e.g. immediately after an injury, then rely on expression of the polypeptide *in vivo* for long-term therapy.

Delivery of polypeptides

Polypeptides of the invention may be delivered by any suitable means. Intravenous delivery is a preferred option. Owing to MGF's short half-life, slow-release on delivery agents may be used. Any suitable pharmaceutical formulation may be used to effect slow-release of MGF of the invention. Liposome formulations are one possibility.

Production of polypeptides

Polypeptides of the invention may be produced in any suitable manner. In some embodiments they may be extracted from animal tissues. However, it is preferred that they be produced recombinantly. This can be done using known techniques.

Delivery of nucleic acids

Delivery by means of a vector containing a nucleic acid encoding the polypeptide, which is then expressed *in vivo,* is preferred in some situations. MGF has a short half-life and may be most effective when provided locally at the neuromuscular junction. *In vivo* expression of MGF facilitates localisation and avoids the need for repeated injection.

-24-

Vectors for delivery of nucleic acids

The nucleic acids of the invention may be delivered in any suitable manner. In particular, they will generally be delivered via a vector. Any suitable type of vector
5   may be used.

The nucleic acid may be delivered in a "naked" form (e.g. in a plasmid vector), optionally associated with an agent to assist in its penetration, as discussed below. Alternatively, the vector may be one that encapsulates the nucleic acid, e.g. a virus.
10

The vector may, for example be a plasmid or cosmid vector.

The vector may be a viral vector, such as a vector comprising a virus able to infect the cells of the recipient subject. Thus, the vector may be, or may be derived from
15   any suitable virus, for example an alphavirus, adenovirus, adeno-associated virus, baculovirus, vaccinia virus, herpes virus, herpes simplex virus, retrovirus (e.g. lentivirus) vector, or baculovirus. A virus vector will be disabled, in the sense that it will not typically be able to replicate or cause pathological effects in the same way as on intact virus. It will typically be attenuated, for example replication defective.
20

Especially when it is delivered in a "naked" form, e.g. as a plasmid, the polynucleotide may be associated with an agent to assist in penetration of cells. Examples include cationic agents (e.g. cationic lipids), polylysine, lipids, and precipitating agents (e.g. a calcium salt). Such agents generally aid the passage of
25   the polynucleotide across the cell membrane. The polynucleotide may be in the form of liposomes or particles, for example in association with any of the penetrating agents mentioned above. The polynucleotide may be in association with an agent that causes the polynucleotide to adopt a more compact form, such as a histone. The polynucleotide may be in association with spermidine.
30

Similarly, liposomes may be used to help transport polynucleotides of the invention

into cells.

The polynucleotide may be associated with a carrier which can be used to deliver the polynucleotide into the cell, or even into the nucleus, using biolistic techniques.

5   Such a carrier may be a metal particle, such as a gold or tungsten particle.

The polynucleotide is typically capable of being expressed in a cell of the recipient. Thus, the polynucleotide typically also comprises control sequences which are operably linked to the MGF coding sequence of the invention, said control sequences

10   being capable of expressing the coding sequence in the cells of the recipient, for example after integration of the polynucleotide into the genome of the cell.

The control sequences typically comprise a promoter (generally 5' to the coding sequence) and/or a terminator and/or translation initiation sequence (e.g.

15   GCCACCATGG (SEQ ID NO. 7) or GCCCCCATGG (SEQ ID NO. 8)) and/or a translational stop codon (e.g. TAA, TAG or TGA) and/or a polyadenylation signal and/or one or more enhancer sequences and/or a RNA pause site. The control sequences may enhance the transcription or translation of the polynucleotide. The control sequences may be tissue-specific so that the polynucleotide is only expressed

20   in certain tissues, or may be the control sequences of a constitutively expressed gene. Muscle-specific promoters and enhancers are particularly preferred. The control sequences are typically those of any of the eukaryotes mentioned herein or of a virus which infects a eukaryote, e.g. of the species of the recipient, such as a human virus for a human recipient. The polynucleotide may comprise an origin of replication.

25

The promoter may, for example be (in particular for expression in mammalian cells) a metallothionein gene promoter, SV40 large T antigen promoter, CMV or adenoviral promoter.

30   So far as tissue-specific expression is concerned, muscle-specific control elements, such as muscle-specific promoters and enhancers, are particularly preferred,

especially where the nucleic acid is to be delivered intramuscularly, e.g. in plasmid form. Such elements can be derived from, for example myosin genes. For example, myosin light chain or heavy chain promoters may be used, as may myosin light chain or heavy chain enhancers.

5

Several myosin enhancers and promoters have been identified to date from both myosin light chain and myosin heavy chain genes. Preferably, the myosin enhancer and/or promoter used is of vertebrate origin, more preferably avian, piscine or mammalian origin.

10

A myosin light chain enhancer is preferred. A rat myosin light chain 1/3 enhancer (Donoghue *et al* (1988) *Genes Dev.* 2:1779-1790; Neville *et al* (1996) *Dev. Genetics* 19:157-162) is especially preferred. The enhancer is operably linked to the promoter. The enhancer may be either upstream or downstream of the promoter. The enhancer

15   may be used in either orientation.

A myosin heavy chain promoter is preferred. A particularly preferred myosin heavy chain promoter is a truncated rabbit β-cardiac myosin heavy chain promoter, in particular up to and including 789 base pairs upstream of the transcriptional start site.

20   Another myosin heavy chain promoter which is preferred is the carp FG2 promoter, in particular up to and including 901 base pairs upstream of the transcription start site (Gauvry *et al* (1996) *Eur. J. Biochem.* 236:887-894). Further details of myosin heavy chain promoters derived from rat, rabbit, human, porcine and chick myosin heavy chain genes are given in Gauvry *et al* (1996) and references therein. All of

25   these promoters may be used in the present invention.

In this context, introduction of MGF of the invention may be linked with physical activity. As muscles respond to exercise and myosin is the most abundant protein in muscle the myosin promoter/enhancer regulatory elements means that the expression

30   of the cDNA will be upregulated by increased muscular activity.

-27-

Plasmid vectors and disabled viral vectors are preferred embodiments. Plasmid
vectors are particularly preferred, especially for intramuscular administration aimed
at securing local expression in the muscle.

5   The vector may be designed for stable integration into the genome of the recipient's
cells. Alternatively, it may be designed to be non-integrative. In stable introduction
the polynucleotide becomes integrated into the genome of the cell (i.e. becomes
contiguous with genome). Thus, the polynucleotide may also comprise a sequence
which enhances integration of the polynucleotide such as the loxP sites of the
10   bacteriophage P1 Cre recombination system, FRT sites of the yeast FLP
recombination system or Adeno-associated virus (AAV) terminal repeat sequences.
Integration may be enhanced by other factors which are present, such as
bacteriophage P1 derived Cre, yeast derived FLP recombinase, AAV Rep proteins,
Cre or FLP recombinases or bacterial Rec proteins. In one embodiment, the
15   polynucleotide of the invention is capable of expressing such a factor.

The polynucleotide may be one which integrates randomly (such as in a non-
sequence specific manner) into any position in the genome or one which
preferentially integrates at particular sites of the genome. Generally the whole
20   coding sequence of the polynucleotide and the control sequences will be present in
the genome after integration.

Pharmaceutical compositions and formulations

25   The polypeptides and nucleic acids of the invention are preferably delivered in the
form of a pharmaceutical formulation comprising a pharmaceutically acceptable
carrier or diluent. Any suitable pharmaceutical formulation may be used.

For example, suitable formulations may include aqueous and non-aqueous sterile
30   injection solutions which may contain anti-oxidants, buffers, bacteriostats,
bactericidal antibiotics and solutes which render the formulation isotonic with the

bodily fluids of the intended recipient; and aqueous and non-aqueous sterile

suspensions which may include suspending agents and thickening agents. The

formulations may be presented in unit-dose or multi-dose containers. For example,

sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized)

5   condition requiring only the addition of the sterile liquid carrier, for example water

for injections, immediately prior to use.

It should be understood that in addition to the ingredients particularly mentioned

above the formulations of this invention may include other agents conventional in the

10   art having regard to the type of formulation in question. Sterile, pyrogen-free

aqueous and non-aqueous solutions are preferred.

Routes of Administration

15   Polypeptides and nucleic acids of the invention may be administered by any suitable

form of administration, for example topical, cutaneous, parenteral, intramuscular,

subcutaneous or transdermal administration, or by direct injection into the

bloodstream or by direct application to mucosal tissues. Intramuscular

administration is preferred for plasmids and other naked nucleic acids.

20

Dosages

The proteins, nucleic acids and vectors of the invention may be delivered in any

suitable dosage, and using any suitable dosage regime. Persons of skill in the art will

25   appreciate that the dosage amount and regime may be adapted to ensure optimal

treatment of the particular condition to be treated, depending on numerous factors.

Some such factors may be in the age, sex and clinical condition of the subject to be

treated.

30   The dosage used for the delivery of nucleic acids by vectors will depend on many

factors, including the efficiency with which the vectors deliver the nucleic acids to

cells, and the efficiency with which the nucleic acids are expressed in the cells.

For the delivery of naked nucleic acids (e.g. plasmids or other naked non-viral vectors), typical doses are from 0.1 to 5000µg, for example 10 to 1000µg, such as 10 to 100µg, 100 to 500µg and 500 to 2000µg per dose.

As a guide, viral vectors may be delivered in doses of from 10^4 to 10^{14} cfu or pfu/ml, for example 10^4 to 10^6, 10^6 to 10^8, 10^8 to 10^{10}, 10^{10} to 10^{12} or 10^{12} to 10^{14} cfu or pfu/ml. Doses in the region of 10^5 to 10^9 cfu or pfu/ml are preferred. The term pfu (plaque forming unit) applies to certain viruses, including adenoviruses, and corresponds to the infectivity of a virus solution, and is determined by infection of an appropriate cell culture, and measurement, generally after 48 hours, of the number of plaques of infected cells. The term cfu (colony forming unit) applies to other viruses, including retroviruses, and is determined by means known in the art generally following 14 days incubation with a selectable marker. The techniques for determining the cfu or pfu titre of a viral solution are well known in the art.

For retroviruses, dosages in the region of 10^5 to 10^6 cfu/ml are particularly preferred. For pseudotyped retroviruses, dosages in the region of 10^7 cfu/ml are particularly preferred. For adenoviruses, dosages in the region of 10^9 pfu/ml are particularly preferred.

For the delivery of polypeptides of the invention suitable doses include doses of from 1 to 1000µg, from 10 to 100µg, from 100 to 500µg and from 500 to 1000µg.

Dosage schedules will also vary according to, for example the route of administration, the species of the recipient and the condition of the recipient. However, single doses and multiple doses spread over periods of days, weeks of months are envisaged. As discussed above, delivery by means of nucleic acids that are expressed *in vivo* is advantageous because it minimises the need for injections into the subject.

cells, and the efficiency with which the nucleic acids are expressed in the cells.

For the delivery of naked nucleic acids (e.g. plasmids or other naked non-viral vectors), typical doses are from 0.1 to 5000µg, for example 10 to 1000µg, such as 10 to 100µg, 100 to 500µg and 500 to 2000µg per dose.

As a guide, viral vectors may be delivered in doses of from 10^4 to 10^{14} cfu or pfu/ml, for example 10^4 to 10^6, 10^6 to 10^8, 10^8 to 10^{10}, 10^{10} to 10^{12} or 10^{12} to 10^{14} cfu or pfu/ml. Doses in the region of 10^5 to 10^9 cfu or pfu/ml are preferred. The term pfu (plaque forming unit) applies to certain viruses, including adenoviruses, and corresponds to the infectivity of a virus solution, and is determined by infection of an appropriate cell culture, and measurement, generally after 48 hours, of the number of plaques of infected cells. The term cfu (colony forming unit) applies to other viruses, including retroviruses, and is determined by means known in the art generally following 14 days incubation with a selectable marker. The techniques for determining the cfu or pfu titre of a viral solution are well known in the art.

For retroviruses, dosages in the region of 10^5 to 10^6 cfu/ml are particularly preferred. For pseudotyped retroviruses, dosages in the region of 10^7 cfu/ml are particularly preferred. For adenoviruses, dosages in the region of 10^9 pfu/ml are particularly preferred.

For the delivery of polypeptides of the invention suitable doses include doses of from 1 to 1000µg, from 10 to 100µg, from 100 to 500µg and from 500 to 1000µg.

Dosage schedules will also vary according to, for example the route of administration, the species of the recipient and the condition of the recipient. However, single doses and multiple doses spread over periods of days, weeks of months are envisaged. As discussed above, delivery by means of nucleic acids that are expressed *in vivo* is advantageous because it minimises the need for injections into the subject.

Neurological disorders

As discussed above, MGF may be used to treat neurological disorders. Treatment of neurodegenerative disorders is preferred. Treatment of motoneurone disorders, especially neurodegenerative disorders of motoneurones is preferred.

Examples of disorders include amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy; infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome; a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; and motoneurone loss associated with ageing; and autosomal as well as sex-linked muscular dystrophy; Alzheimer's disease; Parkinson's disease; diabetic neuropathy; and peripheral neuropathies.

Preferably, the effects of the treatment involve motoneurone rescue. Notably, the present Inventors are the first to appreciate that IGF-I is capable of effecting motoneurone rescue in intact adult motoneurones. Treatments based on adult motoneurone rescue are thus preferred.

Combinations of MGF and other neurotrophic factors

MGF polypeptides and nucleic acids of the invention can be administered in combination with other neurologically active agents. Any additional neurological active agent may be used in this way. Such agents may be non-polypeptide molecules or they may be polypeptides. If they are polypeptides, they may be delivered as polypeptides or as nucleic acids encoding such polypeptides. This may be done by any suitable method, for example by a method as described herein for delivering of MGF or nucleic acids encoding MGF.

Polypeptide growth factors having neurological activity are preferred. For example, neurotophins such as Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3

-31-

(NT-3), NT-4, NT-5 or Nerve Growth Factor (NGF) may be used. Similarly, neurologically active cytokines such as Ciliary Neurotrophic Factor (CNTF) can be used. Similarly, neurologically active transcription factors such as Brn 3a, Brn 3b and Brn 3c may be used.

5

When an MGF of the invention is combined with another neurologically active agent in the treatment of a neurological disorder the two may be combined in the same pharmaceutical composition. Alternatively, they may be administered in separate compositions. They may be administered simultaneously, separately or sequentially

10   and at the same site or a different site.

       EXAMPLES

       Introduction

15

       In this study, we have used a model of axotomy-induced motoneuroneal degeneration in adult rats to examine the protective effects of two isoforms of insulin-like growth factor-I (IGF-I): the commonly-used liver-type isoform (L.IGF-I) and a newly-identified splice variant of IGF-I which is produced by active muscle (Yang *et al*,

20   1996) and which we have termed "mechano growth factor" (MGF). Our analysis of the structure of MGF indicates that it probably has different tissue binding and a shorter half-life than L.IGF-I making it particularly suited to mediating such local interactions in a paracrine/autocrine manner. To enable the local action of L.IGF-I and MGF at the neuromuscular junction and avoid the need for repeated injections of

25   these short half-life molecules, we used a plasmid DNA vector to deliver the genes for these growth factors to muscles.

       Methods

30   Three 20μl equidistant injections were made into the right whisker pad of lightly-anaesthetised (2% halothane) 6m Sprague-Dawley rats (n=4 per group). In the first

-32-

group (plasmid), 1.5μg/μl plasmid DNA containing the rat MGF gene was injected
and in the third group 0.65μg/μl plasmid DNA containing the rat MGF gene was
injected. After 7 days, the right facial nerve was avulsed as it emerged from the
stylomastoid foramen using gentle traction. In other groups, the right facial nerve

5   was crushed (n=4) or avulsed (n=4) without prior intramuscular injection of plasmid.
After 1 month, all rats, including 4 non-operated rats, were anaesthetised then
perfused with 4% paraformaldehyde and the region of the brainstem containing the
facial nucleus sectioned serially at 70μm using a vibratome. Every 5th section was
taken in a systematic random manner and stained with the fluorescent dye YOYO

10   (1:1000, molecular probes) for estimation of total facial motoneurone number using a
modification of the discetor method for use in the confocal microscope (Johnson *et
al*, 1998). Briefly, 2 optical sections separated by 10μm were taken through the
70μm vibratome slice, one image was stored as shades of green and the other as
shades of red. The two optical sections were then merged on screen and only those

15   neurones which were present in one optical section but not the other (which in this
case were green, but not red or shades of yellow) were counted. After determining
the volume of the facial nucleus using stereology (West M.J. Trends in Neuroscience
1999. 22: 51-61) the total number of facial motoneurones was then calculated.

20   **Results**

The normal adult rat facial nucleus contains approximately 3,500 motoneuroes
(Table 1, Figure 1). 1 month following nerve crush, approximately 15% of the
motoneurones are lost ipsilaterally ($p < 0.05$, Mann Whitney U test), while 1 month

25   following nerve avulsion approximately 75% of the motoneurones are lost (Figure 2).
Injection of plasmid DNA alone into the snout 7 days before avulsion had no effect
on the massive motoneuroneal loss seen 1 month later (Figure 3). However, prior
intramuscular injection of the plasmid containing the gene for L.IGF-I reduced the
motoneuroneal loss 1 month following avulsion to 53% and injection of the plasmid

30   containing the MGF gene reduced motoneuroneal loss 1 month following avulsion to
21% (Figure 4).

-33-

TABLE 1

Total numbers of motoneurones in the facial motor nucleus 1 month following nerve avulsion (a simple tug to damage the nerve) with or without prior intramuscular gene transfer

	No avulsion		Crush		Avulsion	
	right	left	right	left	right	left
rat 1	3676	3404	3014	3619	884	3323
rat 2	3622	3118	2889	3404	889	3372
rat 3	3631	3385	2903	3314	719	3397
rat 4	3666	3233	3083	3523	733	3023
mean	3648.7	3285	2972.3	3465	806.3	3278.8
sd	22.8	116.9	80.2	115.8	80.4	150.0

	Control plasmid-avulsion		IGF-avulsion		MGF-avulsion	
	right	left	right	left	right	left
rat 1	750	3384	1699	3386	2674	3624
rat 2	798	3488	1556	3413	2934	3582
rat 3	819	3631	1660	3438	2800	3561
rat 4	869	3606	1640	3655	2823	3429
mean	809	3527.3	1638.8	3473	2807.8	3549
sd	42.7	98.8	52.3	106.7	92.4	72.9

Discussion

Here, we show that intramuscular gene transfer provides a means of influencing nerve/muscle interaction with the system intact. Given that fasciculation persists and motor units continue to enlarge with motoneurone diseased MND (Eisen *et al*, 1998),

-34-

it is likely that the processes leading to motoneuroneal death continue for the most part while neuromuscular contact is maintained. The present results indicate that increased neurotrophic support from muscle prior to nerve injury can afford a long-lasting (1 month) protection against motoneuroneal death. This contrasts with the temporary protection from axotomy-induced motoneuroneal death afforded by neurotrophic factors applied at the time of injury to neonates (Vejsada *et al*, 1995 and 1998) and may in part reflect a method of trophic factor delivery which is better suited for molecules which need to exert local effects, which have short half lives and which are capable of inducing undesirable systemic effects (e.g. disturbances of glucose homeostasis).

We report that both IGF-I isoforms are effective in promoting adult motoneurone rescue, with the isoform produced by active muscle (MGF) being most effective. Our results implicating IGF-I in adult motoneurone rescue may also provide clues about the mechanism of motoneurone loss associated with ageing which has been documented for certain populations of cranial and spinal motoneurones since IGF-I levels decrease with ageing and mutations of a highly conserved homologue of the IGF-I receptor in *Caenorhabditis Elegans* has a profound effect on the ageing process and cell death. It may be the case that decreased neurotrophic support in the form of specific IGF-I isoforms, and especially MGF, increase the likelihood of motoneuroneal death either as part of the ageing process or as a result of minor trauma.

REFERENCES

- Mañes *et al*, *Endocrinology* 138: 905-915 (1997)

- Goldspink *et al*, *J. Physiol.* 4968, 1628 (1996)

- McKoy *et al*, *J. Physiol.* 516.2, 583-592 (1999)

- Chew *et al*, *Endocrinology* 136, No. 5 (1995)

- Layall, *"Transcriptional regulation of the ovine IGF-1 gene"*, PhD Thesis, University of Cambridge (1996)

- Tobin *et al*, *Mol. Endocrinology* 1914-20 (1990)

- Jansen *et al*, *Mol. Cell Endocrinology* 78: 115-25 (1991)

- Rotwein *et al*, *J. Biol. Chem.* 261:4828-3 (1986)

- Skarli *et al*, *J. Physiol.* 509.8, 192.8 (1998)

- Yang *et al*, *Journal of muscle cell research and cell motility* 4: 487-496 (1996)

- Johnson *et al*, *Neuroscience* 84: 141-150 (1998)

- Eisen *et al*, *"Amyotrophic Lateral Sclerosis"* (Cambridge University Press, Cambridge, 1998)

- Vejsada *et al*, *Eur. J. Neurosci.* 7: 108-115 (1995)

- Vesjada *et al*, *Neuroscience* 84: 129-139 (1998)

-36-

CLAIMS

1.   Use of an MGF (mechano-growth factor) Insulin-like Growth Factor I (IGF-I) isoform comprising amino acid sequences encoded by nucleic acid sequences of IGF-I exons 4, 5 and 6 in the reading frame of MGF and having the ability to reduce motoneurone loss by 20% or greater in response to nerve avulsion, in the manufacture of a medicament for the treatment of a neurological disorder.

2.   Use according to claim 1 wherein the MGF has the ability to reduce motoneurone loss by 50% or greater or 80% or greater in response to nerve avulsion.

3.   Use according to claim 1 or 2 wherein the MGF is unglycosylated.

4.   Use according to claim 1, 2 or 3 wherein the MGF has:

(a)   the sequence of Human MGF (SEQ ID NO. 2, Rat MGF (SEQ ID NO. 4) or Rabbit MGF (SEQ ID NO. 6);

(b)   a sequence having 70% or greater homology to a sequence of (a);

(c)   a sequence comprising the amino acids encoded wholly or partly by exons 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5, or a sequence having 70% or greater homology thereto; or

(d)   a sequence encoded by a nucleic acid sequence capable of selectively hybridising to a sequence of (a), (b) or (c).

5.   Use of a polynucleotide encoding an MGF IGF-I isoform as defined in any one of claims 1 to 4 in the manufacture of a medicament for the treatment of a neurological disorder.

6.   Use according to claim 5 wherein the polynucleotide comprises the coding sequence of SEQ ID NO. 1, 3 or 5.

7.   Use according to claim 6 wherein the polynucleotide is contained within a vector.

8.   Use according to claim 7 wherein the vector is a plasmid vector or a disarmed viral vector.

9.   Use according to any one of the preceding claims wherein the neurological disorder is a disorder of motoneurones and/or a neurodegenerative disorder.

10.   Use according to claim 9 wherein the effects of the treatment comprise motoneurone rescue.

11.   Use according to claim 10 wherein the effects of the treatment comprise adult motoneurone rescue.

12.   Use according to claim 9 wherein the disorder is selected from amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy; infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome; a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; motoneurone loss associated with ageing; autosomal or sex-linked muscular dystrophy; diabetic neuropathy; and peripheral neuropathies.

13.   Use according to any one of the preceding claims wherein the medicament further comprises another neurologically active agent or wherein treatment with the MGF is carried out in combination with another neurologically active agent.

14.   A product comprising an MGF IGF-I isoform as defined in any one of claims 1 to 4 or an MGF-encoding polynucleotide as defined in any of claims 5 to 8 and another neurologically active agent for simultaneous, separate or sequential use in the treatment of a neurological disorder.

-38-

15.   A product according to claim 14 for use in the treatment of a disorder as defined in any one of claims 9 to 12.

16.   A pharmaceutical composition comprising an MGF IGF-I isoform as defined in any one of claims 1 to 4 or an MGF-encoding polynucleotide as defined in any one of claims 5 to 8, another neurologically active agent and a pharmaceutically acceptable carrier.

17.   A method of treating a neurological disorder comprising administering to a subject in need thereof an effective amount of an IGF-I isoform as defined in any one of claims 1 to 4 or a nucleic acid encoding an MGF IGF-I isoform as defined in any one of claims 5 to 8, optionally in combination with another neurologically active agent.

18.   Use according to claim 13, a product according to claim 14 or 15, a composition according to claim 16 or a method according to claim 17 wherein the other neurologically active agent is a polypeptide growth factor or a nucleic acid encoding a polypeptide growth factor.

Fig.1.

Fig.2.

Avulsion

Fig.3.
Plasmid

non-op

op

Fig.4.
MGF Plasmid

op

non-op

Fig.5.

cDNA sequence of Human MGF

Exon 3
GGACCGGAGAGACGCTCTGCGGGGGCTGAGCTGGTGGATGCTCTTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCAACAGCCCACAGGGTATGGCTCCAGCAGTCGG

Exon 4
AGGGGCGCCTCAGACAGGCATCGTGGATGAGTGCTGCTTCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGTCTGCCAAGTCAGTCGCTC

Exon 5
TGTCCGTGCCCAGCGCCACCGACATGCCCAGAGACCCAGAAGTATCAGCCCCCATCTACCAACAAGAACACGAAGTCTCAGAGAAGGAAAGGAAGTACATTTGAAG

AACACAAGTAGAGGGAGTGCAGGAAACAAGAACTACAGGATGTAGAAGACCCTTCTGAGGAGTGAAGAAGGACAGGCCACCGCAGGACCCTTTGCTCTGCACAGTTA

Exon 6
CCTGTAAACATTGGAATACCGGCCAAAAAATAAGTTTGATCACATTTCAAAGATGGCATTTCCCCAATGAAATACACAAGTAAACAT

Protein sequence of Human MGF

Exon 3
GlyProGluThrLeuCysGlyAlaGluLeuValAlaAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerAr

Exon 4
gArgAlaProGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysSerAlaArgS

Exon 5
erValArgAlaGlnArgHisThrAspMetProLysThrGlnLysTyrGlnProProSerThrAsnLysAsnThrLysSerGlnArgArgLysGlySerThrPheGlu

Exon 6
GluHisLys

Fig.6.

cDNA sequence of Rat MGF

Exon 3

GGACCAGAGACCCTTTGCGGGGCTGAGCTGGTGGACGCTCTTCAGTTCGTGTGTGGACCAAGGGGCTTTTACTTCAACAAGCCCACAGTCTATGGCTCCAGCATTCG

Exon 4

GAGGGCACCACAGACGGGCATTGTGGATGAGTGTTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGTCCGCTGCAAGCCTACAAAGTCAGCTCGTT

Exon 5

CCATCCGGGCCCCAGCGCCCACACTGACATGCCCAGACTCAGAAGTCCCAGCCCCTATCGACACACAAGAAAAGGAAGCTGCAAAGGAGGAAGGAAGTACACTT

GAAGAACAACAAGAGGAAGTGCAGGAAACAAGACCTACAGAATGTAGGAGGAGCCTCCCGAGGAACAGAAAATGCCACGTCACCGCCAAGATCCTTTGCTGCTTGA

Exon 6

GCAACCTGCAAAACATCGGAACACCTGCCAAATATCAATATCATTCAGAGATGGGCATTTCCCTCAATGAAATACACAAGTAAACATTCCCGGA

ATTC

Protein sequence of Rat MGF

Exon 3

GlyProGluThrLeuCysGlyAlaAlaLeuValAspAlaLeuGlnPheValCysGlyProArgGlyPheTyrPheAsnLysProThrValTyrGlySerSerIleAr

Exon 4

gArgAlaProGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysValArgCysLysProThrLysSerAlaArgS

Exon 5

erIleArgAlaGlnArgHisThrAspMetProLysThrGlnLysSerThrHisLysLysArgLysLeuGlnArgArgArgLysGlySerThrLeu

Exon 6

GluGluHisLys

Fig.7.

cDNA sequence of Rabbit MGF

Exon 3

GGACCGGAGACGCTCTGCGGTGCTGCTGAGCTGGTGGATGCTCTTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCAACAAGCCCACAGGATACGGCTCCAGCAGTCGGAGGGCACC

Exon 4

TCAGACAGGCATCTGGATGAGTGCTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGCACCCCTCAAGCGCCGGCAAAGGCAGCCGCTCCGTCCGTGCCCAGCGCC

Exon 5

ACACCGACATGCCCAAGACTCAGAGCTAYCAGCCTCCAATCTACCAACAAGAAAATGAAGTCTCAGAGGAGGAAAAGGAAGGAGTACATTTGAAGAACACAAGTAGAGGGAGTGCAGG

AAACAAGAACTACACAGGATGTAGGAAGACCCCTTTCTGAGGAGTGAAGAAGGACCAGGCCACCGCAGGACCCTTTGCTCTGCACAGTTACCTGTAAACATTGGAATACCGGCCAAAAAAT

Exon 6

AAGTTTGATCACATTTCAAAGATGGCATTTCCCCCAATGAAAATACACAAGTAAACATTC

Protein sequence of Rabbit MGF

Exon 3

GlyProGluThrLeuCysGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerSerArgArgAlaPr

Exon 4

oGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysAlaAlaArgSerValArgAlaGlnArgH

Exon 5

isThrAspMetProLysThrGlnLysTyrGlnProProSerThrAsnLysLysMetLysSerGlnArgArgArgLysGlySerThrPheGluGluHisLys

Exon 6

Fig.8.

cDNA sequence of Human L.IGF-1

Exon 3

GGACCGGAGAGCGCTCTGCGGGGCTGAGCTGGTGGATGCTCTTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCAACAAGCCCACAGGGTATGGCTCGGAGGGCGCC

Exon 4

TCAGACAGGCATCGTGGATGAGTGCTGCTTCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGTCGCTCTGTCCGTGCCCAGCGCC

Exon 6

ACACCGACATGCCCAAGACCCAGAAGGAAGTACATTTGAAGAACCCAAGTAGAGGGAGTCCAGGAAACAAGAACTACAGGATGTAG

Protein sequence of Human L.IGF-1

Exon 3

GlyProGluThrLeuCysGlyAlaGlyAlaGluLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerSerArgArgAlaPr

Exon 4

oGlnPheGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysSerAlaArgSerValArgAlaGlnArgH

Exon 6

isThrAspMetProLysThrGlnLysGluValHisLeuLysAsnAlaSerArgGlySerAlaGlyAsnLysAsnTyrArgMet

Fig.9.

cDNA sequence of Rat L.IGF-1

Exon 3
GGACCAGAGAGACCCTTTGCGGGGGCTGAGCTGGTGGACGCCTCTTCAGTTCGTCGTGTGTGGACCAAGGGGGCTTTTACTTCAACAAGCCCACAGTCTATGGCTCCAGCATTCGGAGGGCACC

Exon 4
ACAGACGGGCATTGTGTGATGAGTGTTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGTCCGCTGCAAGCCTACAAAGTCAGCTCGTTCCATCCGGGCCCAGCGCC

Exon 6
ACACTGACATGCCCAAGACTCAGAAGGAAGTACACTTGAAGAACACAAGAGGAAGTGCAGGAAACAAGACCTACAGAATGTAGGAGGAGCCTCCCGAGGAACAGAAAATGCCA

CGTCACCGCCAAGATCCTTTGCTGCTTGAGCAACCTGCCAAAATATCAATATCATTTCCCTCAATGAAATAC

ACAAGTAAACATTCCCGGAATTC

Protein sequence of Rat L.IGF-1

Exon 3
GlyProGluThrLeuCysGlyAlaAlaGluLeuValAspAlaLeuGlnPheValCysGlyProArgGlyPheTyrPheAsnLysProThrValTyrGlySerSerIleArgArgAlaPr

Exon 4
oGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysValArgCysLysProThrLysSerAlaArgSerIleArgAlaGlnArgH

Exon 6
isThrAspMetProLysThrGlnLysGluValHisLeuLysLeuAsnThrSerArgGlySerAlaGlyAsnLysTyrTyrArgMet

SUBSTITUTE SHEET (RULE 26)

Fig.10.

cDNA sequence of Rabbit L.IGF-1

Exon 4

Exon 3
GGACCGGGAGAGACGCTCTGCGGTGCTGAGCTGGTGGATGCTCCTTCAGTTCGTGTGTGGAGACAGGGGCTTTTATTTCAACAAGCCCACAGGATACGGCTCCAGCAGTCGGAGGGCACC

TCAGACAGGCATCGTGGATGAGTGCTGCTTCCGGAGCTGTGATCTGAGGAGGCTGGAGATGTACTGTGCACCCCTCAAGCCGGCAAAGGCAGCCCGCTCCGTCCGTCCCAGCGCC

Exon 6
ACACCGACATGCCCAAGACTCAGAAGAAGAAGTACATTTGAAGAACAACAAGTAGAGGGAGTGCAGGAAACAAGAACTACAGGATCGTPAGGAGTGAAGAAGGACA

GGCCACCGCCAGGACCCTTTGCTCTGCACAGTTACCTGTAAACATTGGAATACCGGCCAAAAAATAAGTTTGATCACATTTCAAAGATGGCATTTCCCCAATGAAATACACACAAGTA

AACATTC

Protein sequence of Rabbit L.IGF-1

Exon 4

Exon 3
GlyProGlnThrLeuCysGlyAlaGlnLeuValAspAlaLeuGlnPheValCysGlyAspArgGlyPheTyrPheAsnLysProThrGlyTyrGlySerSerSerArgArgAlaPr

pGlnThrGlyIleValAspGluCysCysPheArgSerCysAspLeuArgArgLeuGluMetTyrCysAlaProLeuLysProAlaLysAlaAlaArgSerValArgAlaGlnArgH

Exon 6
isThrAspMetProLysThrGlnLysLysLysTyrSerArgGlySerAlaGlyAsnLysLysAsnTyrArgMet

Fig.11.

Exon 4

```
Hu  MGF - A|sn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe
Rat MGF - A|sn Lys Pro Thr Val Tyr Gly Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe
Rab MGF - A|sn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe
Hu  IGF - A|sn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Ser Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe
Rat IGF - A|sn Lys Pro Thr Val Tyr Gly Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe
Rab IGF - A|sn Lys Pro Thr Gly Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys Phe

Hu  MGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala Arg Ser Val
Rat MGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys Lys Pro Thr Lys Ser Ala Arg Ser Ile
Rab MGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala Arg Ser Val
Hu  IGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala Arg Ser Val
Rat IGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys Lys Pro Thr Lys Ser Ala Arg Ser Ile
Rab IGF - Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys Ala Arg Ser Val
```

Exon 5

```
Hu  MGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr Lys
Rat MGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|Ser Gln Pro Leu Ser Thr His Lys Lys Arg Lys
Rab MGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met Lys
Hu  IGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|--------------------
Rat IGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|--------------------
Rab IGF - Arg Ala Gln Arg His Thr Asp Met Pro Lys Thr Gln Lys|--------------------
```

Exon 6

```
Hu  MGF - Ser Gln  Arg Arg Lys G|ly Ser Thr Phe Glu Glu His Lys
Rat MGF - Leu Gln Arg Arg Lys G|ly Ser Thr Leu Glu Glu His Lys
Rab MGF - Ser Gln Arg Arg Lys G|ly Ser Thr Phe Glu Glu His Lys
Hu  IGF - --------|Glu Val His Leu Lys Asn Ala Ser Arg Gly Ser Ala Gly Asn Lys Asn Tyr Arg Met
Rat IGF - --------|Glu Val His Leu Lys Asn Thr Ser Arg Gly Ser Ala Gly Asn Lys Asn Thr Tyr Arg Met
Rab IGF - --------|Glu Val His Leu Lys Asn Thr Ser Arg Gly Ser Ala Gly Asn Lys Asn Tyr Arg Met
```

-1-

SEQUENCE LISTING

<110> UNIVERSITY COLLEGE LONDON

<120> TREATMENT OF NEUROLOGICAL DISORDERS

<130> N77091C TAC AB

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 518

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(330)

<400> 1

```
gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc    48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
  1               5                  10                  15

gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca ggg tat ggc    96
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
             20                  25                  30

tcc agc agt cgg agg gcg cct cag aca ggc atc gtg gat gag tgc tgc   144
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35                  40                  45

ttc cgg agc tgt gat cta agg agg ctg gag atg tat tgc gca ccc ctc   192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
    50                  55                  60
```

```
aag cct gcc aag tca gct cgc tct gtc cgt gcc cag cgc cac acc gac  240
Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65               70              75              80

atg ccc aag acc cag aag tat cag ccc cca tct acc aac aag aac acg  288
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr
                 85              90              95

aag tct cag aga agg aaa gga agt aca ttt gaa gaa cac aag          330
Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
                 100             105             110

tagagggagt gcaggaaaca agaactacag gatgtagaa gacccttctg aggagtgaag 390
aaggacaggc caccgcagga ccctttgctc tgcacagtta cctgtaaaca ttggaatacc450
ggccaaaaaa taagtttgat cacatttcaa agatggcatt tcccccaatg aaatacacaa510
gtaaacat                                                          518
```

```
<210> 2
<211> 110
<212> PRT
<213> Homo sapiens


<400> 2
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5               10              15
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
                 20              25              30
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35              40              45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
 50              55              60
Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65              70              75              80
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Asn Thr
```

```
                    85                    90                    95
      Lys Ser Gln Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
                    100                   105                   110
```

<210> 3
<211> 539
<212> DNA
<213> Rat

<220>
<221> CDS
<222> (1)..(333)

<400> 3

```
gga cca gag acc ctt tgc ggg gct gag ctg gtg gac gct ctt cag ttc    48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
  1               5                    10                  15
gtg tgt gga cca agg ggc ttt tac ttc aac aag ccc aca gtc tat ggc    96
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
                  20                   25                  30
tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc    144
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
              35                   40                  45
ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc    192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
          50                   55                  60
aag cct aca aag tca gct cgt tcc atc cgg gcc cag cgc cac act gac    240
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
  65                   70                   75                  80
atg ccc aag act cag aag tcc cag ccc cta tcg aca cac aag aaa agg    288
Met Pro Lys Thr Gln Lys Ser Gln Pro Leu Ser Thr His Lys Lys Arg
```

-4-

```
                85                  90                  95
aag ctg caa agg aga agg aaa gga agt aca ctt gaa gaa cac aag        333
Lys Leu Gln Arg Arg Arg Lys Gly Ser Thr Leu Glu Glu His Lys
            100                 105                 110
tagaggaagt gcaggaaaca agacctacag aatgtaggag gagcctcccg aggaacagaa393
aatgccacgt caccgcaaga tcctttgctg cttgagcaac ctgcaaaaca tcggaacacc453
tgccaaatat caataatgag ttcaatatca tttcagagat gggcatttcc ctcaatgaaa513
tacacaagta aacattcccg gaattc                                      539
```

<210> 4

<211> 111

<212> PRT

<213> Rat

<400> 4

```
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5                  10                  15
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
                20                  25                  30
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
            35                  40                  45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
        50                  55                  60
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
65                  70                  75                  80
Met Pro Lys Thr Gln Lys Ser Gln Pro Leu Ser Thr His Lys Lys Arg
                85                  90                  95
Lys Leu Gln Arg Arg Arg Lys Gly Ser Thr Leu Glu Glu His Lys
            100                 105                 110
```

<210> 5

<211> 523

<212> DNA

<213> RABBIT

<220>

<221> CDS

<222> (1)..(333)

<400> 5

```
gga ccg gag acg ctc tgc ggt gct gag ctg gtg gat gct ctt cag ttc   48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5                  10                  15

gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca gga tac ggc   96
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
             20                  25                  30

tcc agc agt cgg agg gca cct cag aca ggc atc gtg gat gag tgc tgc  144
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35                  40                  45

ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gca ccc ctc  192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
     50                  55                  60

aag ccg gca aag gca gcc cgc tcc gtc cgt gcc cag cgc cac acc gac  240
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65                  70                  75                  80

atg ccc aag act cag aag tat cag cct cca tct acc aac aag aaa atg  288
Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met
                 85                  90                  95

aag tct cag agg aga agg aaa gga agt aca ttt gaa gaa cac aag       333
Lys Ser Gln Arg Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
             100                 105                 110

tagagggagt gcaggaaaca agaactacag gatgtaggaa gacccttctg aggagtgaag 393
```

-6-

aaggacaggc caccgcagga ccctttgctc tgcacagtta cctgtaaaca ttggaatacc453
ggccaaaaaa taagtttgat cacatttcaa agatggcatt tcccccaatg aaatacacaa513
gtaaacattc   523

<210> 6
<211> 111
<212> PRT
<213> RABBIT

<400> 6

Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1   5   10   15

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
                20   25   30

Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
            35   40   45

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
        50   55   60

Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
65   70   75   80

Met Pro Lys Thr Gln Lys Tyr Gln Pro Pro Ser Thr Asn Lys Lys Met
                85   90   95

Lys Ser Gln Arg Arg Arg Lys Gly Ser Thr Phe Glu Glu His Lys
            100   105   110

<210> 7
<211> 10
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
       initiation sequence

<400> 7
gccaccatgg   10

<210> 8
<211> 10
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: translation
       initiation sequence

<400> 8
gcccccatgg   10

<210> 9
<211> 316
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)..(315)

<400> 9
gga ccg gag acg ctc tgc ggg gct gag ctg gtg gat gct ctt cag ttc   48

```
    Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
     1               5                  10                  15

    gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca ggg tat ggc    96
    Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
                     20                  25                  30

    tcc agc agt cgg agg gcg cct cag aca ggc atc gtg gat gag tgc tgc   144
    Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
                     35                  40                  45

    ttc cgg agc tgt gat cta agg agg ctg gag atg tat tgc gca ccc ctc   192
    Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
         50                  55                  60

    aag cct gcc aag tca gct cgc tct gtc cgt gcc cag cgc cac acc gac   240
    Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
     65                  70                  75                  80

    atg ccc aag acc cag aag gaa gta cat ttg aag aac gca agt aga ggg   288
    Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly
                     85                  90                  95

    agt gca gga aac aag aac tac agg atg ag                             317
```

    Ser Ala Gly Asn Lys Asn Tyr Arg Met
             100   105

    <210> 10
    <211> 105
    <212> PRT
    <213> Homo sapiens

    <400> 10
    Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe

```
       1                5                      10                    15
     Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
                     20                     25                    30
     Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
                      35                    40                    45
     Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
              50                    55                    60
     Lys Pro Ala Lys Ser Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
     65                    70                    75                    80
     Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Ala Ser Arg Gly
                          85                    90                    95
     Ser Ala Gly Asn Lys Asn Tyr Arg Met
                 100                   105
```


<210> 11

<211> 487

<212> DNA

<213> Rat

<220>

<221> CDS

<222> (1)..(315)

<400> 11

```
gga cca gag acc ctt tgc ggg gct gag ctg gtg gac gct ctt cag ttc    48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5                      10                    15
gtg tgt gga cca agg ggc ttt tac ttc aac aag ccc aca gtc tat ggc    96
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
                 20                     25                    30
```

-10-

```
tcc agc att cgg agg gca cca cag acg ggc att gtg gat gag tgt tgc  144
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
            35                  40                  45
ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gtc cgc tgc  192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
        50                  55                  60
aag cct aca aag tca gct cgt tcc atc cgg gcc cag cgc cac act gac  240
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
 65                  70                  75                  80
atg ccc aag act cag aag gaa gta cac ttg aag aac aca agt aga gga  288
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
                85                  90                  95
agt gca gga aac aag acc tac aga atg taggaggagc ctcccgagga          335
Ser Ala Gly Asn Lys Thr Tyr Arg Met
                100                 105
acagaaaatg ccacgtcacc gcaagatcct ttgctgcttg agcaacctgc aaaacatcgg395
aacacctgcc aaatatcaat aatgagttca atatcatttc agagatgggc atttccctca455
atgaaataca caagtaaaca ttcccggaat tc                                487
```

<210> 12
<211> 105
<212> PRT
<213> Rat

<400> 12
```
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5                  10                  15
Val Cys Gly Pro Arg Gly Phe Tyr Phe Asn Lys Pro Thr Val Tyr Gly
            20                  25                  30
```

-11-

```
Ser Ser Ile Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35                  40                  45
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Val Arg Cys
    50              ·    55                  60
Lys Pro Thr Lys Ser Ala Arg Ser Ile Arg Ala Gln Arg His Thr Asp
.65                  70                  75                  80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
                 85                  90                  95
Ser Ala Gly Asn Lys Thr Tyr Arg Met
             100                 105
```

```
<210> 13
<211> 471
<212> DNA
<213> Rabbit

<220>
<221> CDS
<222> (1)..(315)

<400> 13
gga ccg gag acg ctc tgc ggt gct gag ctg gtg gat gct ctt cag ttc    48
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1               5                  10                  15
gtg tgt gga gac agg ggc ttt tat ttc aac aag ccc aca gga tac ggc    96
Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
             20                  25                  30
tcc agc agt cgg agg gca cct cag aca ggc atc gtg gat gag tgc tgc   144
```

-12-

```
Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35                  40                  45

ttc cgg agc tgt gat ctg agg agg ctg gag atg tac tgt gca ccc ctc   192
Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
         50                  55                  60

aag ccg gca aag gca gcc cgc tcc gtc cgt gcc cag cgc cac acc gac   240
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65                  70                  75                  80

atg ccc aag act cag aag gaa gta cat ttg aag aac aca agt aga ggg   288
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
                 85                  90                  95

agt gca gga aac aag aac tac agg atg taggaagacc cttctgagga          335
Ser Ala Gly Asn Lys Asn Tyr Arg Met
                 100                 105

gtgaagaagg acaggccacc gcaggaccct ttgctctgca cagttacctg taaacattgg395
aataccggcc aaaaaataag tttgatcaca tttcaaagat ggcatttccc ccaatgaaat455
acacaagtaa acattc                                                  471
```

<210> 14

<211> 105

<212> PRT

<213> Rabbit

<400> 14

```
Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe
 1                  5                  10                  15

Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
                 20                  25                  30

Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp Glu Cys Cys
         35                  40                  45

Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
```

```
            50                      55                      60
Lys Pro Ala Lys Ala Ala Arg Ser Val Arg Ala Gln Arg His Thr Asp
 65                      70                      75                      80
Met Pro Lys Thr Gln Lys Glu Val His Leu Lys Asn Thr Ser Arg Gly
                        85                      90                      95
Ser Ala Gly Asn Lys Asn Tyr Arg Met
                100                     105
```

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   C07K14/65   A61K38/30   A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7   C07K   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and. where practical. search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, STRAND, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document. with indication. where appropriate. of the relevant passages	Relevant to claim No.
X	WO 97 33997 A (GOLDSPINK GEOFFREY ;ROYAL FREE HOSP SCHOOL MED (GB)) 18 September 1997 (1997-09-18) cited in the application	1-12
Y	the whole document	13-18
Y	YANG S ET AL: "CLONING AND CHARACTERIZATION OF AN IGF-1 ISOFORM EXPRESSED IN SKELETAL MUSCLE SUBJECTED TO STRETCH" JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY,GB,CHAPMAN, LONDON, vol. 17, no. 4, 1 August 1996 (1996-08-01), pages 487-495, XP000677224 ISSN: 0142-4319 cited in the application the whole document	1-18

-/--

| X | Further documents are listed in the continuation of box C. | X | Patent family members are listed in annex. |

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 March 2001	3 0. 03. 01

Name and mailing address of the ISA	Authorized officer
European Patent Office. P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040. Tx. 31 651 epo nl. Fax: (+31–70) 340–3016	Morawetz, R

Form PCT/ISA/210 (second sheet) (July 1992)

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document. with indication.where appropriate. of the relevant passages	Relevant to claim No.
Y	GOLDSPINK GEOFFREY: "Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload." JOURNAL OF ANATOMY, vol. 194, no. 3, April 1999 (1999-04), pages 323-334, XP000984889 ISSN: 0021-8782 the whole document	1-18
Y	GOLDSPINK G ET AL: "LOCAL GROWTH REGULATION IS ASSOCIATED WITH AN ISOFORM OF IGF-1 THATIS EXPRESSED IN NORMAL MUSCLES BUT NOT IN DYSTROPHIC MDX OF DYDY MOUSE MUSCLES WHEN SUBJECTED TO STRETCH" JOURNAL OF PHYSIOLOGY,XX,XX, vol. 495P, 2 July 1996 (1996-07-02), pages 162P-163P, XP000677210 ISSN: 0022-3751 the whole document	1-18
Y	CHEW S L ET AL: "AN ALTERNATIVELY SPLICED HUMAN INSULIN-LIKE GROWTH FACTOR-I TRANSCRIPT WITH HEPATIC TISSUE EXPRESSION THAT DIVERTS AWAY FROM THE MITOGENIC IBE1 PEPTIDE" ENDOCRINOLOGY,US,BALTIMORE, MD, vol. 136, no. 5, 1 May 1995 (1995-05-01), pages 1939-1944, XP000676528 ISSN: 0013-7227 cited in the application the whole document	4,5,9-18
Y	ROTWEIN P: "Two insulin-like growth factor I messenger RNAs are expressed in human liver" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 83, January 1986 (1986-01), pages 77-81, XP002033834 ISSN: 0027-8424 the whole document	4,5,9-18

-/--

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category°	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
Y	CARONI P ET AL: "Signaling by insulin-like growth factors in paralyzed skeletal muscle: Rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4" JOURNAL OF NEUROSCIENCE,US,NEW YORK, NY, vol. 14, no. 5, PART 02, May 1994 (1994-05), pages 3378-3388, XP002115584 ISSN: 0270-6474 the whole document	1-18
Y	CARONI P ET AL: "Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4" JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, NEW YORK, US, vol. 125, no. 4, May 1994 (1994-05), pages 893-902, XP002115589 ISSN: 0021-9525 the whole document	1-18
Y	DORE SYLVAIN ET AL: "Rediscovering an old friend, IGF-I: Potential use in the treatment of neurodegenerative diseases." TRENDS IN NEUROSCIENCES, vol. 20, no. 8, 1997, pages 326-331, XP000942231 ISSN: 0166-2236 the whole document	1-18
Y	H ALILA ET AL: "Expression of biologically active human Insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats" HUMAN GENE THERAPY,XX,XX, vol. 8, no. 15, 10 October 1997 (1997-10-10), pages 1785-1795, XP002118452 ISSN: 1043-0342 the whole document	1-18

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

> Although claims 17 and 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

Inter ''onal Application No
PCT/GB 00/04354

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9733997 A	18-09-1997	EP 0894136 A JP 2000506729 T	03-02-1999 06-06-2000